Ligand Pharmaceuticals | LGND - Capital Social Ordinario

Precio De Mercado
231.27
Cambio Diario
2.79 1.22%
Mensual
13.06%
Anual
114.00%
Q2 Expectativa
226.32




Capital Social Ordinario Cambio Fecha
Agenus USD 35.32M 2.51M 2025-12
Amgen USD 539M 1000K 2025-12
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 135.7M 2.44M 2025-09
Baxter International USD 514.28M 168.72M 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 946.83M 354.23M 2025-06
Enanta Pharmaceuticals USD 212K 1000 2023-12
Enviri Corporation USD 81.45M 797K 2025-12
Gilead Sciences USD 1.24B 1000K 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Glaxosmithkline GBP 4.08B 49.43M 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Intrexon USD 0 0 2024-06
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.32M 60K 2025-12
Merck USD 2.49B 15.79M 2025-09
Pacira USD 41.12M 1.85M 2025-12
Pfizer USD 5.69B 1000K 2025-09
Rigel Pharmaceuticals USD 17K 158K 2024-06
Veracyte USD 79.05M 377K 2025-12